Bray F.; Laversanne M.; Weiderpass E.; Soerjomataram I.; The ever‐increasing importance of cancer as a leading cause of premature death worldwide. Cancer 2021,127(16),3029-3030
[DOI:
10.1002/cncr.33587]
Chen S.; Cao Z.; Prettner K.; Kuhn M.; Yang J.; Jiao L.; Wang Z.; Li W.; Geldsetzer P.; Bärnighausen T.; Bloom D.E.; Wang C.; Estimates and projections of the global economic cost of 29 cancers in 204 countries and territories from 2020 to 2050. JAMA Oncol 2023,9(4),465-472
[DOI:
10.1001/jamaoncol.2022.7826]
Guida F.; Kidman R.; Ferlay J.; Schüz J.; Soerjomataram I.; Kithaka B.; Ginsburg O.; Mailhot Vega R.B.; Galukande M.; Parham G.; Vaccarella S.; Canfell K.; Ilbawi A.M.; Anderson B.O.; Bray F.; dos-Santos-Silva I.; McCormack V.; Global and regional estimates of orphans attributed to maternal cancer mortality in 2020. Nat Med 2022,28(12),2563-2572
[DOI:
10.1038/s41591-022-02109-2]
Ferlay J.; Ervik M.; Lam F.; Laversanne M.; Colombet M.; Mery L.; Piñeros M.; Znaor A.; Soerjomataram I.; Bray F.; Global Cancer Observatory: Cancer Today 2024
Ferlay J.; Colombet M.; Soerjomataram I.; Parkin D.M.; Piñeros M.; Znaor A.; Bray F.; Cancer statistics for the year 2020: An overview. Int J Cancer 2021,149(4),778-789
[DOI:
10.1002/ijc.33588]
Sung H.; Ferlay J.; Siegel R.L.; Laversanne M.; Soerjomataram I.; Jemal A.; Bray F.; Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021,71(3),209-249
[DOI:
10.3322/caac.21660]
Ali I.; Lone M.; Al-Othman Z.; Al-Warthan A.; Sanagi M.; Heterocyclic scaffolds: Centrality in anticancer drug development. Curr Drug Targets 2015,16(7),711-734
[DOI:
10.2174/1389450116666150309115922]
Hamama W.S.; Ismail M.A.; Soliman M.; Shaaban S.; Zoorob H.H.; Behavior of 2‐iminothiazolidin‐4‐one with different reagents. J Heterocycl Chem 2011,48(5),1169-1174
[DOI:
10.1002/jhet.628]
Abdel-Wahab B.; Shaaban S.; Thiazolothiadiazoles and thiazolooxadiazoles: Synthesis and biological applications. Synthesis 2014,46(13),1709-1716
[DOI:
10.1055/s-0033-1338627]
Sayed A.R.; Al-Faiyz Y.S.; Elsawy H.; Shaaban S.; Mohamed M.A.; Synthesis and biochemical studies of novel Mon-Azothiazoles and Bis-Azothiazoles based on 2-(4-(Dimethylamino)Benzylidene)Hydrazine-1-Carbothioamide. Polycycl Aromat Compd 2023,43(3),2644-2655
[DOI:
10.1080/10406638.2022.2049326]
Meusel M.; Gütschow M.; Recent developments in hydantoin chemistry. A review. Org Prep Proced Int 2004,36(5),391-443
[DOI:
10.1080/00304940409356627]
Cho S.; Kim S.H.; Shin D.; Recent applications of hydantoin and thiohydantoin in medicinal chemistry. Eur J Med Chem 2019,164,517-545
[DOI:
10.1016/j.ejmech.2018.12.066]
Mezoughi A.B.; Mohammed W.A.; Ettarhouni Z.O.; Recent biological applications and chemical synthesis of Thiohydantoins. J Chem Rev 2021,1(3),196-218
[DOI:
10.22034/jcr.2021.285244.1111]
Kumar V.; Designed synthesis of diversely substituted hydantoins and hydantoin-based hybrid molecules: A personal account. Synlett 2021,32(19),1897-1910
[DOI:
10.1055/a-1480-6474]
Ware E.; The chemistry of the hydantoins. Chem Rev 1950,46(3),403-470
[DOI:
10.1021/cr60145a001]
Sallam A.A.; Mohyeldin M.M.; Foudah A.I.; Akl M.R.; Nazzal S.; Meyer S.A.; Liu Y.Y.; El Sayed K.A.; Marine natural products-inspired phenylmethylene hydantoins with potent in vitro and in vivo antitumor activities via suppression of Brk and FAK signaling. Org Biomol Chem 2014,12(28),5295-5303
[DOI:
10.1039/C4OB00553H]
Liton A.K.; Islam M.R.; Synthesis of hydantoin and thiohydantoin related compounds from benzil and study of their cytotoxicity. Bangladesh J Pharmacol 2008,1(1),10-15
[DOI:
10.3329/bjp.v1i1.481]
Zhang M.; Liang Y.R.; Li H.; Liu M.M.; Wang Y.; Design, synthesis, and biological evaluation of hydantoin bridged analogues of combretastatin A-4 as potential anticancer agents. Bioorg Med Chem 2017,25(24),6623-6634
[DOI:
10.1016/j.bmc.2017.10.045]
Xie H.; Liang J.J.; Wang Y.L.; Hu T.X.; Wang J.Y.; Yang R.H.; Yan J.K.; Zhang Q.R.; Xu X.; Liu H.M.; Ke Y.; The design, synthesis and anti-tumor mechanism study of new androgen receptor degrader. Eur J Med Chem 2020,204,112512
[DOI:
10.1016/j.ejmech.2020.112512]
Jung M.E.; Ouk S.; Yoo D.; Sawyers C.L.; Chen C.; Tran C.; Wongvipat J.; Structure-activity relationship for thiohydantoin androgen receptor antagonists for castration-resistant prostate cancer (CRPC). J Med Chem 2010,53(7),2779-2796
[DOI:
10.1021/jm901488g]
Zhang N.; Ma S.; Recent development of membrane-active molecules as antibacterial agents. Eur J Med Chem 2019,184,111743
[DOI:
10.1016/j.ejmech.2019.111743]
Handzlik J.; Szymańska E.; Chevalier J.; Otrębska E.; Kieć-Kononowicz K.; Pagès J.M.; Alibert S.; Amine–alkyl derivatives of hydantoin: New tool to combat resistant bacteria. Eur J Med Chem 2011,46(12),5807-5816
[DOI:
10.1016/j.ejmech.2011.09.032]
Fujisaki F.; Shoji K.; Shimodouzono M.; Kashige N.; Miake F.; Sumoto K.; Antibacterial activity of 5-dialkylaminomethylhydantoins and related compounds. Chem Pharm Bull (Tokyo) 2010,58(8),1123-1126
[DOI:
10.1248/cpb.58.1123]
Sondhi S.M.; Singh J.; Kumar A.; Jamal H.; Gupta P.P.; Synthesis of amidine and amide derivatives and their evaluation for anti-inflammatory and analgesic activities. Eur J Med Chem 2009,44(3),1010-1015
[DOI:
10.1016/j.ejmech.2008.06.029]
Lesuisse D.; Mauger J.; Nemecek C.; Maignan S.; Boiziau J.; Harlow G.; Hittinger A.; Ruf S.; Strobel H.; Nair A.; Ritter K.; Malleron J.L.; Dagallier A.; El-Ahmad Y.; Guilloteau J.P.; Guizani H.; Bouchard H.; Venot C.; Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: Advantages in comparison with competitive inhibitors. Bioorg Med Chem Lett 2011,21(8),2224-2228
[DOI:
10.1016/j.bmcl.2011.03.003]
Sergent D.; Wang Q.; Sasaki N.A.; Ouazzani J.; Synthesis of hydantoin analogues of (2S,3R,4S)-4-hydroxyisoleucine with insulinotropic properties. Bioorg Med Chem Lett 2008,18(15),4332-4335
[DOI:
10.1016/j.bmcl.2008.06.081]
Ghasempour L.; Asghari S.; Tajbakhsh M.; Mohseni M.; One‐pot synthesis of new hydantoin (thiohydantoin) derivatives and evaluation of their antibacterial and antioxidant activities. J Heterocycl Chem 2020,57(12),4136-4148
[DOI:
10.1002/jhet.4120]
Marzouk A.A.; Bass A.K.A.; Ahmed M.S.; Abdelhamid A.A.; Elshaier Y.A.M.M.; Salman A.M.M.; Aly O.M.; Design, synthesis and anticonvulsant activity of new imidazolidindione and imidazole derivatives. Bioorg Chem 2020,101,104020
[DOI:
10.1016/j.bioorg.2020.104020]
Zhu Q.; Pan Y.; Xu Z.; Li R.; Qiu G.; Xu W.; Ke X.; Wu L.; Hu X.; Synthesis and potential anticonvulsant activity of new N-3-substituted 5,5-cyclopropanespirohydantoins. Eur J Med Chem 2009,44(1),296-302
[DOI:
10.1016/j.ejmech.2008.02.024]
Stilz H.U.; Guba W.; Jablonka B.; Just M.; Klingler O.; König W.; Wehner V.; Zoller G.; Discovery of an orally active non-peptide fibrinogen receptor antagonist based on the hydantoin scaffold. J Med Chem 2001,44(8),1158-1176
[DOI:
10.1021/jm001068s]
Pękala E.; Stadnicka K.; Broda A.; Zygmunt M.; Filipek B.; Kieć-Kononowicz K.; Synthesis, structure–activity relationship of some new anti-arrhythmic 5-arylidene imidazolidine-2,4-dione derivatives. Eur J Med Chem 2005,40(3),259-269
[DOI:
10.1016/j.ejmech.2004.11.006]
Kieć-Kononowicz K.; Stadnicka K.; Mitka A.; Pekala E.; Filipek B.; Sapa J.; Zygmunt M.; Synthesis, structure and antiarrhythmic properties evaluation of new basic derivatives of 5,5-diphenylhydantoin. Eur J Med Chem 2003,38(6),555-566
[DOI:
10.1016/S0223-5234(03)00075-8]
Nishinami S.; Ikeda K.; Nagao T.; Koyama A.H.; Arakawa T.; Shiraki K.; Aromatic interaction of hydantoin compounds leads to virucidal activities. Biophys Chem 2021,275,106621
[DOI:
10.1016/j.bpc.2021.106621]
Kim D.; Wang L.; Caldwell C.G.; Chen P.; Finke P.E.; Oates B.; MacCoss M.; Mills S.G.; Malkowitz L.; Gould S.L.; DeMartino J.A.; Springer M.S.; Hazuda D.; Miller M.; Kessler J.; Danzeisen R.; Carver G.; Carella A.; Holmes K.; Lineberger J.; Schleif W.A.; Emini E.A.; Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection. Bioorg Med Chem Lett 2001,11(24),3103-3106
[DOI:
10.1016/S0960-894X(01)00655-2]
Nique F.; Hebbe S.; Triballeau N.; Peixoto C.; Lefrançois J.M.; Jary H.; Alvey L.; Manioc M.; Housseman C.; Klaassen H.; Van Beeck K.; Guédin D.; Namour F.; Minet D.; Van der Aar E.; Feyen J.; Fletcher S.; Blanqué R.; Robin-Jagerschmidt C.; Deprez P.; Identification of a 4-(hydroxymethyl)diarylhydantoin as a selective androgen receptor modulator. J Med Chem 2012,55(19),8236-8247
[DOI:
10.1021/jm300281x]
Li J.J.; Iula D.M.; Nguyen M.N.; Hu L.Y.; Dettling D.; Johnson T.R.; Du D.Y.; Shanmugasundaram V.; Van Camp J.A.; Wang Z.; Harter W.G.; Yue W.S.; Boys M.L.; Wade K.J.; Drummond E.M.; Samas B.M.; Lefker B.A.; Hoge G.S.; Lovdahl M.J.; Asbill J.; Carroll M.; Meade M.A.; Ciotti S.M.; Krieger-Burke T.; Rational design and synthesis of 4-((1R,2R)-2-hydroxycyclohexyl)-2(trifluoromethyl)benzonitrile (PF-998425), a novel, nonsteroidal androgen receptor antagonist devoid of phototoxicity for dermatological indications. J Med Chem 2008,51(21),7010-7014
[DOI:
10.1021/jm8009316]
He Y.; Hwang D.J.; Ponnusamy S.; Thiyagarajan T.; Mohler M.L.; Narayanan R.; Miller D.D.; Exploration and biological evaluation of basic heteromonocyclic propenamide derivatives as sards for the treatment of enzalutamide-resistant prostate cancer. J Med Chem 2021,64(15),11045-11062
[DOI:
10.1021/acs.jmedchem.1c00439]
He Y.; Hwang D.J.; Ponnusamy S.; Thiyagarajan T.; Mohler M.L.; Narayanan R.; Miller D.D.; Pyrazol-1-yl-propanamides as SARD and pan-antagonists for the treatment of enzalutamide-resistant prostate cancer. J Med Chem 2020,63(21),12642-12665
[DOI:
10.1021/acs.jmedchem.0c00943]
Zhang Z.; Connolly P.J.; Lim H.K.; Pande V.; Meerpoel L.; Teleha C.; Branch J.R.; Ondrus J.; Hickson I.; Bush T.; Luistro L.; Packman K.; Bischoff J.R.; Ibrahim S.; Parrett C.; Chong Y.; Gottardis M.M.; Bignan G.; Discovery of JNJ-63576253: A clinical stage androgen receptor antagonist for F877L mutant and wild-type castration-resistant prostate cancer (mCRPC). J Med Chem 2021,64(2),909-924
[DOI:
10.1021/acs.jmedchem.0c01563]
Flick A.C.; Leverett C.A.; Ding H.X.; McInturff E.; Fink S.J.; Helal C.J.; DeForest J.C.; Morse P.D.; Mahapatra S.; O’Donnell C.J.; Synthetic approaches to new drugs approved during 2018. J Med Chem 2020,63(19),10652-10704
[DOI:
10.1021/acs.jmedchem.0c00345]
Wu X.; Feng W.; Yang M.; Liu X.; Gao M.; Li X.; Gan L.; He T.; HC-1119, a deuterated Enzalutamide, inhibits migration, invasion and metastasis of the AR-positive triple-negative breast cancer cells. Mol Biol Rep 2022,49(10),9231-9240
[DOI:
10.1007/s11033-022-07749-8]
Li X.; Cheng K.; Li X.; Zhou Y.; Liu J.; Zeng H.; Chen Y.; Liu X.; Zhang Y.; Wang Y.; Bi F.; Zheng L.; Phase I clinical trial of HC‐1119: A deuterated form of enzalutamide. Int J Cancer 2021,149(7),1473-1482
[DOI:
10.1002/ijc.33706]
Konnert L.; Lamaty F.; Martinez J.; Colacino E.; Recent advances in the synthesis of Hydantoins: The state of the art of a valuable scaffold. Chem Rev 2017,117(23),13757-13809
[DOI:
10.1021/acs.chemrev.7b00067]
Blackadar C.B.; Historical review of the causes of cancer. World J Clin Oncol 2016,7(1),54-86
[DOI:
10.5306/wjco.v7.i1.54]
Sudani B.R.; The multifaceted biological activities of Hydantoin derivatives: From antimicrobial to anticancer agents. Bioscan 2024,19,88-92
[DOI:
10.63001/tbs.2024.v19.i02.S2.pp]
Sunil D.; Kamath P.; Multi-target directed indole based hybrid molecules in cancer therapy: An up-to-date evidence-based review. Curr Top Med Chem 2017,17(9),959-985
[DOI:
10.2174/1568026616666160927150839]
Pettit G.R.; Herald C.L.; Leet J.E.; Gupta R.; Schaufelberger D.E.; Bates R.B.; Clewlow P.J.; Doubek D.L.; Manfredi K.P.; Rützler K.; Schmidt J.M.; Tackett L.P.; Ward F.B.; Bruck M.; Camou F.; Antineoplastic agents. 168. Isolation and structure of axinohydantoin. Can J Chem 1990,68(9),1621-1624
[DOI:
10.1139/v90-250]
Nishizuka Y.; The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature 1984,308(5961),693-698
[DOI:
10.1038/308693a0]
Patil A.D.; Freyer A.J.; Killmer L.; Hofmann G.; Johnson R.K.; Z-Axinohydantoin and Debromo-Z-Axinohydantoin from the sponge Stylotella aurantium: Inhibitors of protein kinase C. Nat Prod Lett 1997,9(3),201-207
[DOI:
10.1080/10575639708048315]
Castillo A.; Justice M.J.; The kinesin related motor protein, Eg5, is essential for maintenance of pre-implantation embryogenesis. Biochem Biophys Res Commun 2007,357(3),694-699
[DOI:
10.1016/j.bbrc.2007.04.021]
Waitzman J.S.; Rice S.E.; Mechanism and regulation of kinesin‐5, an essential motor for the mitotic spindle. Biol Cell 2014,106(1),1-12
[DOI:
10.1111/boc.201300054]
Hotha S.; Yarrow J.C.; Yang J.G.; Garrett S.; Renduchintala K.V.; Mayer T.U.; Kapoor T.M.; HR22C16: A potent small-molecule probe for the dynamics of cell division. Angew Chem Int Ed 2003,42(21),2379-2382
[DOI:
10.1002/anie.200351173]
Barnes D.W.; Growth characteristics of A431 human epidermoid carcinoma cells in serum-free medium: Inhibition by epidermal growth factor. Adv Exp Med Biol 1984,172,49-66
[DOI:
10.1007/978-1-4615-9376-8_4]
Wykosky J.; Fenton T.; Furnari F.; Cavenee W.K.; Therapeutic targeting of epidermal growth factor receptor in human cancer: Successes and limitations. Chin J Cancer 2011,30(1),5-12
[DOI:
10.5732/cjc.010.10542]
Carmi C.; Cavazzoni A.; Zuliani V.; Lodola A.; Bordi F.; Plazzi P.V.; Alfieri R.R.; Petronini P.G.; Mor M.; 5-benzylidene-hydantoins as new EGFR inhibitors with antiproliferative activity. Bioorg Med Chem Lett 2006,16(15),4021-4025
[DOI:
10.1016/j.bmcl.2006.05.010]
Cavazzoni A.; Alfieri R.R.; Carmi C.; Zuliani V.; Galetti M.; Fumarola C.; Frazzi R.; Bonelli M.; Bordi F.; Lodola A.; Mor M.; Petronini P.G.; Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines. Mol Cancer Ther 2008,7(2),361-370
[DOI:
10.1158/1535-7163.MCT-07-0477]
El-Deeb I.M.; Bayoumi S.M.; El-Sherbeny M.A.; Abdel-Aziz A.A.M.; Synthesis and antitumor evaluation of novel cyclic arylsulfonylureas: ADME-T and pharmacophore prediction. Eur J Med Chem 2010,45(6),2516-2530
[DOI:
10.1016/j.ejmech.2010.02.038]
Zhao E.; Hou J.; Ke X.; Abbas M.N.; Kausar S.; Zhang L.; Cui H.; The roles of sirtuin family proteins in cancer progression. Cancers 2019,11(12),1949
[DOI:
10.3390/cancers11121949]
Sacconnay L.; Ryckewaert L.; Randazzo G.M.; Petit C.; Passos C.D.S.; Jachno J.; Michailovienė V.; Zubrienė A.; Matulis D.; Carrupt P.A.; Simões-Pires C.A.; Nurisso A.; 5-Benzylidene-hydantoin is a new scaffold for SIRT inhibition: From virtual screening to activity assays. Eur J Pharm Sci 2016,85,59-67
[DOI:
10.1016/j.ejps.2016.01.010]
Pustenko A.; Nocentini A.; Gratteri P.; Bonardi A.; Vozny I.; Žalubovskis R.; Supuran C.T.; The antibiotic furagin and its derivatives are isoform-selective human carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2020,35(1),1011-1020
[DOI:
10.1080/14756366.2020.1752201]
Lannuzel M.; Lamothe M.; Schambel P.; Etiévant C.; Hill B.; Perez M.; From pure FPP to mixed FPP and CAAX competitive inhibitors of farnesyl protein transferase. Bioorg Med Chem Lett 2003,13(8),1459-1462
[DOI:
10.1016/S0960-894X(03)00171-9]
Rajabi M.; Mansell D.; Freeman S.; Bryce R.A.; Structure–activity relationship of 2,4,5-trioxoimidazolidines as inhibitors of thymidine phosphorylase. Eur J Med Chem 2011,46(4),1165-1171
[DOI:
10.1016/j.ejmech.2011.01.035]
Liang X.; Fu H.; Xiao P.; Fang H.; Hou X.; Design, synthesis and biological evaluation of imidazolidine-2,4-dione and 2-thioxothiazolidin-4-one derivatives as lymphoid-specific tyrosine phosphatase inhibitors. Bioorg Chem 2020,103,104124
[DOI:
10.1016/j.bioorg.2020.104124]
Rajic Z.; Zorc B.; Raic-Malic S.; Ester K.; Kralj M.; Pavelic K.; Balzarini J.; De Clercq E.; Mintas M.; Hydantoin derivatives of L- and D-amino acids: synthesis and evaluation of their antiviral and antitumoral activity. Molecules 2006,11(11),837-848
[DOI:
10.3390/11110837]
Graves B.; Thompson T.; Xia M.; Janson C.; Lukacs C.; Deo D.; Di Lello P.; Fry D.; Garvie C.; Huang K.S.; Gao L.; Tovar C.; Lovey A.; Wanner J.; Vassilev L.T.; Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization. Proc Natl Acad Sci USA 2012,109(29),11788-11793
[DOI:
10.1073/pnas.1203789109]
Wang G.; Wang Y.; Wang L.; Han L.; Hou X.; Fu H.; Fang H.; Design, synthesis and preliminary bioactivity studies of imidazolidine-2,4-dione derivatives as Bcl-2 inhibitors. Bioorg Med Chem 2015,23(23),7359-7365
[DOI:
10.1016/j.bmc.2015.10.023]
Liu J.; Zhang K.; Mai X.; Wei J.; Liao Y.; Zhong Y.; Liu Y.; Feng L.; Liu C.; Synthesis, anticancer evaluation and docking study of 3-benzyloxyhydantoin derivatives. Med Chem 2016,12(1),37-47
[DOI:
10.2174/1573406411666150708111631]
Zhong B.; Vatolin S.; Idippily N.D.; Lama R.; Alhadad L.A.; Reu F.J.; Su B.; Structural optimization of non-nucleoside DNA methyltransferase inhibitor as anti-cancer agent. Bioorg Med Chem Lett 2016,26(4),1272-1275
[DOI:
10.1016/j.bmcl.2016.01.020]
Lasko L.M.; Jakob C.G.; Edalji R.P.; Qiu W.; Montgomery D.; Digiammarino E.L.; Hansen T.M.; Risi R.M.; Frey R.; Manaves V.; Shaw B.; Algire M.; Hessler P.; Lam L.T.; Uziel T.; Faivre E.; Ferguson D.; Buchanan F.G.; Martin R.L.; Torrent M.; Chiang G.G.; Karukurichi K.; Langston J.W.; Weinert B.T.; Choudhary C.; de Vries P.; Kluge A.F.; Patane M.A.; Van Drie J.H.; Wang C.; McElligott D.; Kesicki E.; Marmorstein R.; Sun C.; Cole P.A.; Rosenberg S.H.; Michaelides M.R.; Lai A.; Bromberg K.D.; Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. Nature 2017,550(7674),128-132
[DOI:
10.1038/nature24028]
Harras M.F.; Sabour R.; Design, synthesis and biological evaluation of novel 1,3,4-trisubstituted pyrazole derivatives as potential chemotherapeutic agents for hepatocellular carcinoma. Bioorg Chem 2018,78,149-157
[DOI:
10.1016/j.bioorg.2018.03.014]
Obradović A.; Matić M.; Ognjanović B.; Đurđević P.; Marinković E.; Ušćumlić G.; Božić B.; Božić Nedeljković B.; Antiproliferative and antimigratory effects of 3-(4-substituted benzyl)-5-isopropyl-5-phenylhydantoin derivatives in human breast cancer cells. Saudi Pharm J 2020,28(3),246-254
[DOI:
10.1016/j.jsps.2020.01.003]
Roth H.S.; Hergenrother P.J.; Derivatives of procaspase-activating compound 1 (PAC-1) and their anticancer activities. Curr Med Chem 2016,23(3),201-241
[DOI:
10.2174/0929867323666151127201829]
Furutachi M.; Ota K.; Fujisaki F.; Ikeda R.; Yoshikawa N.; Yokota T.; Takeda Y.; Yokomizo K.; Zhou J.R.; Kashige N.; Miake F.; Sumoto K.; Anti-proliferative activities of some bivalent symmetrical 5-substituted hydantoin derivatives towards human brain glioma U251 cells (U251) and human carcinoma cells (KB3-1). Biol Pharm Bull 2019,42(11),1953-1956
[DOI:
10.1248/bpb.b19-00486]
McNally V.A.; Gbaj A.; Douglas K.T.; Stratford I.J.; Jaffar M.; Freeman S.; Bryce R.A.; Identification of a novel class of inhibitor of human and Escherichia coli thymidine phosphorylase by in silico screening. Bioorg Med Chem Lett 2003,13(21),3705-3709
[DOI:
10.1016/j.bmcl.2003.08.010]
Trisovic N.; Bozic B.; Obradovic A.; Stefanovic O.; Markovic S.; Comic L.; Bozic B.; Uscumlic G.; Structure-activity relationships of 3-substituted-5,5- diphenylhydantoins as potential antiproliferative and antimicrobial agents. J Serb Chem Soc 2011,76(12),1597-1606
[DOI:
10.2298/JSC110314143T]
Alanazi A.M.; El-Azab A.S.; Al-Swaidan I.A.; Maarouf A.R.; El-Bendary E.R.; Abu El-Enin M.A.; Abdel-Aziz A.A.M.; Synthesis, single-crystal, in vitro antitumor evaluation and molecular docking of 3-substitued 5,5-diphenylimidazolidine-2,4-dione derivatives. Med Chem Res 2013,22(12),6129-6142
[DOI:
10.1007/s00044-013-0597-1]
Hmuda S.; Trišović N.; Rogan J.; Poleti D.; Vitnik Ž.; Vitnik V.; Valentić N.; Božić B.; Ušćumlić G.; New derivatives of hydantoin as potential antiproliferative agents: Biological and structural characterization in combination with quantum chemical calculations. Monatsh Chem 2014,145(5),821-833
[DOI:
10.1007/s00706-013-1149-6]
Żesławska E.; Kincses A.; Spengler G.; Nitek W.; Wyrzuc K.; Kieć-Kononowicz K.; Handzlik J.; The 5-aromatic hydantoin-3-acetate derivatives as inhibitors of the tumour multidrug resistance efflux pump P-glycoprotein (ABCB1): Synthesis, crystallographic and biological studies. Bioorg Med Chem 2016,24(12),2815-2822
[DOI:
10.1016/j.bmc.2016.04.055]
Alkahtani H.M.; Alanazi M.M.; Aleanizy F.S.; Alqahtani F.Y.; Alhoshani A.; Alanazi F.E.; Almehizia A.A.; Abdalla A.N.; Alanazi M.G.; El-Azab A.S.; Abdel-Aziz A.A.M.; Synthesis, anticancer, apoptosis-inducing activities and EGFR and VEGFR2 assay mechanistic studies of 5,5-diphenylimidazolidine-2,4-dione derivatives: Molecular docking studies. Saudi Pharm J 2019,27(5),682-693
[DOI:
10.1016/j.jsps.2019.04.003]
Hassanin M.A.; Mustafa M.; Abourehab M.A.S.; Hassan H.A.; Aly O.M.; Beshr E.A.M.; Design and synthesis of new hydantoin acetanilide derivatives as anti-NSCLC targeting EGFRL858R/T790M mutations. Pharmaceuticals 2022,15(7),857
[DOI:
10.3390/ph15070857]
Lee J.; Kim J.; Koh J.S.; Chung H.H.; Kim K.H.; Hydantoin derivatives as non-peptidic inhibitors of Ras farnesyl transferase. Bioorg Med Chem Lett 2006,16(7),1954-1956
[DOI:
10.1016/j.bmcl.2005.12.074]
Ashraf H.; A.; Dalal A, A-E.; Nermin S, A.; Bernard D, G.; Jose T, T.; Heather N, T.; Adam B, K.; Gary A, P. Synthesis of novel tadalafil analogues and their evaluation as phosphodiesterase inhibitors and anticancer agents. Arzneimittelforschung 2011,59(8),415-421
[DOI:
10.1055/s-0031-1296417]
Abadi A.H.; Gary B.D.; Tinsley H.N.; Piazza G.A.; Abdel-Halim M.; Synthesis, molecular modeling and biological evaluation of novel tadalafil analogues as phosphodiesterase 5 and colon tumor cell growth inhibitors, new stereochemical perspective. Eur J Med Chem 2010,45(4),1278-1286
[DOI:
10.1016/j.ejmech.2009.10.046]
Mohamed H.A.; Girgis N.M.R.; Wilcken R.; Bauer M.R.; Tinsley H.N.; Gary B.D.; Piazza G.A.; Boeckler F.M.; Abadi A.H.; Synthesis and molecular modeling of novel tetrahydro-β-carboline derivatives with phosphodiesterase 5 inhibitory and anticancer properties. J Med Chem 2011,54(2),495-509
[DOI:
10.1021/jm100842v]
Abadi A.H.; Lehmann J.; Piazza G.A.; Abdel-Halim M.; Ali M.S.M.; Synthesis, molecular modeling, and biological evaluation of novel tetrahydro-β-carboline hydantoin and tetrahydro-β-carboline thiohydantoin derivatives as phosphodiesterase 5 inhibitors. Int J Med Chem 2011,2011,1-9
[DOI:
10.1155/2011/562421]
Ahmed N.S.; Ali A.H.; El-Nashar S.M.; Gary B.D.; Fajardo A.M.; Tinsley H.N.; Piazza G.A.; Negri M.; Abadi A.H.; Exploring the PDE5 H-pocket by ensemble docking and structure-based design and synthesis of novel β-carboline derivatives. Eur J Med Chem 2012,57,329-343
[DOI:
10.1016/j.ejmech.2012.09.029]
Shankaraiah N.; Nekkanti S.; Chudasama K.J.; Senwar K.R.; Sharma P.; Jeengar M.K.; Naidu V.G.M.; Srinivasulu V.; Srinivasulu G.; Kamal A.; Design, synthesis and anticancer evaluation of tetrahydro-β-carboline-hydantoin hybrids. Bioorg Med Chem Lett 2014,24(23),5413-5417
[DOI:
10.1016/j.bmcl.2014.10.038]
Zheng H.; Wu Y.; Sun B.; Cheng C.; Qiao Y.; Jiang Y.; Zhao S.; Xie Z.; Tan J.; Lou H.; Discovery of furyl/thienyl β-carboline derivatives as potent and selective PDE5 inhibitors with excellent vasorelaxant effect. Eur J Med Chem 2018,158,767-780
[DOI:
10.1016/j.ejmech.2018.09.028]
Yao C.H.; Hsieh T.C.; Song J.S.; Lee J.C.; Design, synthesis and anticancer evaluation of β-carboline-1-one hydantoins. Future Med Chem 2020,12(3),183-192
[DOI:
10.4155/fmc-2019-0276]
Basappa; Ananda Kumar, C.S.; Nanjunda Swamy, S.; Sugahara, K.; Rangappa, K.S. Anti-tumor and anti-angiogenic activity of novel hydantoin derivatives: Inhibition of VEGF secretion in liver metastatic osteosarcoma cells. Bioorg Med Chem 2009,17(14),4928-4934
[DOI:
10.1016/j.bmc.2009.06.004]
Ananda Kumar C.S.; Prasad S.B.B.; Vinaya K.; Chandrappa S.; Thimmegowda N.R.; Ranganatha S.R.; Swarup S.; Rangappa K.S.; Synthesis and antiproliferative activity of substituted diazaspiro hydantoins: A structure-activity relationship study. Invest New Drugs 2009,27(2),131-139
[DOI:
10.1007/s10637-008-9150-3]
Kavitha C.V.; Nambiar M.; Narayanaswamy P.B.; Thomas E.; Rathore U.; Ananda Kumar C.S.; Choudhary B.; Rangappa K.S.; Raghavan S.C.; Propyl-2-(8-(3,4-difluorobenzyl)-2′,5′-dioxo-8-azaspiro[bicyclo[3.2.1] octane-3,4′-imidazolidine]-1′-yl) acetate induces apoptosis in human leukemia cells through mitochondrial pathway following cell cycle arrest. PLoS One 2013,8(7),e69103
[DOI:
10.1371/journal.pone.0069103]
Michaelides M.R.; Kluge A.; Patane M.; Van Drie J.H.; Wang C.; Hansen T.M.; Risi R.M.; Mantei R.; Hertel C.; Karukurichi K.; Nesterov A.; McElligott D.; de Vries P.; Langston J.W.; Cole P.A.; Marmorstein R.; Liu H.; Lasko L.; Bromberg K.D.; Lai A.; Kesicki E.A.; Discovery of spiro oxazolidinediones as selective, orally bioavailable inhibitors of p300/cbp histone acetyltransferases. ACS Med Chem Lett 2018,9(1),28-33
[DOI:
10.1021/acsmedchemlett.7b00395]
Upadhyay N.; Tilekar K.; Loiodice F.; Anisimova N.Y.; Spirina T.S.; Sokolova D.V.; Smirnova G.B.; Choe J.; Meyer-Almes F.J.; Pokrovsky V.S.; Lavecchia A.; Ramaa C.S.; Pharmacophore hybridization approach to discover novel pyrazoline-based hydantoin analogs with anti-tumor efficacy. Bioorg Chem 2021,107,104527
[DOI:
10.1016/j.bioorg.2020.104527]
Żesławska E.; Kucwaj-Brysz K.; Kincses A.; Spengler G.; Szymańska E.; Czopek A.; Marć M.A.; Kaczor A.; Nitek W.; Domínguez-Álvarez E.; Latacz G.; Kieć-Kononowicz K.; Handzlik J.; An insight into the structure of 5-spiro aromatic derivatives of imidazolidine-2,4-dione, a new group of very potent inhibitors of tumor multidrug resistance in T-lymphoma cells. Bioorg Chem 2021,109,104735
[DOI:
10.1016/j.bioorg.2021.104735]
Zagórska A.; Czopek A.; Jaromin A.; Mielczarek-Puta M.; Struga M.; Stary D.; Bajda M.; Design, synthesis, and in vitro antiproliferative activity of hydantoin and purine derivatives with the 4-acetylphenylpiperazinylalkyl moiety. Materials 2021,14(15),4156
[DOI:
10.3390/ma14154156]
Peng G.W.; Marquez V.E.; Driscoll J.S.; Potential central nervous system antitumor agents. Hydantoin derivatives. J Med Chem 1975,18(8),846-849
[DOI:
10.1021/jm00242a019]
Bakalova A.; Varbanov H.; Buyukliev R.; Momekov G.; Ferdinandov D.; Konstantinov S.; Ivanov D.; Synthesis, characterization and biological activity of Pt(II) and Pt(IV) complexes with 5-methyl-5(4-pyridyl)-2,4-imidazolidenedione. Eur J Med Chem 2008,43(5),958-965
[DOI:
10.1016/j.ejmech.2007.06.025]
Bakalova A.; Buyukliev R.; Varbanov H.; Momekov G.; Design, synthesis and comparative cytotoxic investigation of platinum(II) complexes with some derivatives of 5-methyl-5-(4-pyridyl)hydantoin. Inorg Chim Acta 2014,423,46-51
[DOI:
10.1016/j.ica.2014.07.030]
Leban J.; Blisse M.; Krauss B.; Rath S.; Baumgartner R.; Seifert M.H.J.; Proteasome inhibition by peptide-semicarbazones. Bioorg Med Chem 2008,16(8),4579-4588
[DOI:
10.1016/j.bmc.2008.02.042]
Khanfar M.A.; Asal B.A.; Mudit M.; Kaddoumi A.; El Sayed K.A.; The marine natural-derived inhibitors of glycogen synthase kinase-3β phenylmethylene hydantoins: In vitro and in vivo activities and pharmacophore modeling. Bioorg Med Chem 2009,17(16),6032-6039
[DOI:
10.1016/j.bmc.2009.06.054]
Khanfar M.A.; El Sayed K.A.; Phenylmethylene hydantoins as prostate cancer invasion and migration inhibitors. CoMFA approach and QSAR analysis. Eur J Med Chem 2010,45(11),5397-5405
[DOI:
10.1016/j.ejmech.2010.08.066]
Xia Z.; Knaak C.; Ma J.; Beharry Z.M.; McInnes C.; Wang W.; Kraft A.S.; Smith C.D.; Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem 2009,52(1),74-86
[DOI:
10.1021/jm800937p]
Reddy Y.T.; Sekhar K.R.; Sasi N.; Reddy P.N.; Freeman M.L.; Crooks P.A.; Novel substituted (Z)-5-((N-benzyl-1H-indol-3-yl)methylene)imidazolidine-2,4-diones and 5-((N-benzyl-1H-indol-3-yl)methylene)pyrimidine-2,4,6(1H,3H,5H)-triones as potent radio-sensitizing agents. Bioorg Med Chem Lett 2010,20(2),600-602
[DOI:
10.1016/j.bmcl.2009.11.082]
Thirupathi Reddy Y.; Narsimha Reddy P.; Koduru S.; Damodaran C.; Crooks P.A.; Aplysinopsin analogs: Synthesis and anti-proliferative activity of substituted (Z)-5-(N-benzylindol-3-ylmethylene)imidazolidine-2,4-diones. Bioorg Med Chem 2010,18(10),3570-3574
[DOI:
10.1016/j.bmc.2010.03.054]
Malancona S.; Altamura S.; Filocamo G.; Kinzel O.; Hernando J.I.M.; Rowley M.; Scarpelli R.; Steinkühler C.; Jones P.; Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclopropyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydroimid azo[1,5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies, Part 1. Bioorg Med Chem Lett 2011,21(15),4422-4428
[DOI:
10.1016/j.bmcl.2011.06.024]
Kinzel O.; Alfieri A.; Altamura S.; Brunetti M.; Bufali S.; Colaceci F.; Ferrigno F.; Filocamo G.; Fonsi M.; Gallinari P.; Malancona S.; Hernando J.I.M.; Monteagudo E.; Orsale M.V.; Palumbi M.C.; Pucci V.; Rowley M.; Sasso R.; Scarpelli R.; Steinkühler C.; Jones P.; Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclo- propyl]-N-(1-phenyl-1H-pyrazol-5-yl)hexahydro-imidazo[1,5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in Hedgehog pathway dependent malignancies, Part 2. Bioorg Med Chem Lett 2011,21(15),4429-4435
[DOI:
10.1016/j.bmcl.2011.06.023]
Azizmohammadi M.; Khoobi M.; Ramazani A.; Emami S.; Zarrin A.; Firuzi O.; Miri R.; Shafiee A.; 2H-chromene derivatives bearing thiazolidine-2,4-dione, rhodanine or hydantoin moieties as potential anticancer agents. Eur J Med Chem 2013,59,15-22
[DOI:
10.1016/j.ejmech.2012.10.044]
Yamaguchi M.; Miyazaki M.; Kodrasov M.P.; Rotinsulu H.; Losung F.; Mangindaan R.E.P.; de Voogd N.J.; Yokosawa H.; Nicholson B.; Tsukamoto S.; Spongiacidin C, a pyrrole alkaloid from the marine sponge Stylissa massa, functions as a USP7 inhibitor. Bioorg Med Chem Lett 2013,23(13),3884-3886
[DOI:
10.1016/j.bmcl.2013.04.066]
Youssef D.; Shaala L.; Alshali K.; Bioactive hydantoin alkaloids from the red sea marine sponge Hemimycale arabica. Mar Drugs 2015,13(11),6609-6619
[DOI:
10.3390/md13116609]
Vitale R.M.; Thellung S.; Tinto F.; Solari A.; Gatti M.; Nuzzo G.; Ioannou E.; Roussis V.; Ciavatta M.L.; Manzo E.; Florio T.; Amodeo P.; Identification of the hydantoin alkaloids parazoanthines as novel CXCR4 antagonists by computational and in vitro functional characterization. Bioorg Chem 2020,105,104337
[DOI:
10.1016/j.bioorg.2020.104337]
Donnier-Maréchal M.; Larchanché P.E.; Le Broc D.; Furman C.; Carato P.; Melnyk P.; Carboline- and phenothiazine-derivated heterocycles as potent SIGMA-1 protein ligands. Eur J Med Chem 2015,89,198-206
[DOI:
10.1016/j.ejmech.2014.10.053]
Ali W.; Spengler G.; Kincses A.; Nové M.; Battistelli C.; Latacz G.; Starek M.; Dąbrowska M.; Honkisz-Orzechowska E.; Romanelli A.; Rasile M.M.; Szymańska E.; Jacob C.; Zwergel C.; Handzlik J.; Discovery of phenylselenoether-hydantoin hybrids as ABCB1 efflux pump modulating agents with cytotoxic and antiproliferative actions in resistant T-lymphoma. Eur J Med Chem 2020,200,112435
[DOI:
10.1016/j.ejmech.2020.112435]
Dong J.; Pan X.; Yang Y.; Zhang G.; Xiao Z.; Liu Z.; Design, synthesis and biological evaluation of exiguamine A analogues as IDO1 inhibitors. Eur J Med Chem 2021,223,113631
[DOI:
10.1016/j.ejmech.2021.113631]
Zask A.; Birnberg G.; Cheung K.; Kaplan J.; Niu C.; Norton E.; Yamashita A.; Beyer C.; Krishnamurthy G.; Greenberger L.M.; Loganzo F.; Ayral-Kaloustian S.; D-piece modifications of the hemiasterlin analog HTI-286 produce potent tubulin inhibitors. Bioorg Med Chem Lett 2004,14(16),4353-4358
[DOI:
10.1016/j.bmcl.2004.05.005]
Abdellatif K.R.A.; Fadaly W.A.A.; Mostafa Y.A.; Zaher D.M.; Omar H.A.; Thiohydantoin derivatives incorporating a pyrazole core: Design, synthesis and biological evaluation as dual inhibitors of topoisomerase-I and cycloxygenase-2 with anti-cancer and anti-inflammatory activities. Bioorg Chem 2019,91,103132
[DOI:
10.1016/j.bioorg.2019.103132]
Abu Ali O.A.; Abd El-Fattah W.; Alfaifi M.Y.; Shati A.A.; Elbehairi S.E.I.; Abu Almaaty A.H.; Elshaarawy R.F.M.; Fayad E.; New Mn(III)/Fe(III) complexes with thiohydantoin-supported imidazolium ionic liquids for breast cancer therapy. Inorg Chim Acta 2023,551,121460
[DOI:
10.1016/j.ica.2023.121460]
Chang X.; Zhang D.; Qu F.; Xie Y.; Chen T.; Zhang Y.; Du Q.; Bian J.; Li Z.; Wang J.; Xu X.; Discovery of thiohydantoin based antagonists of androgen receptor with efficient degradation for the treatment of prostate cancer. Eur J Med Chem 2023,257,115490
[DOI:
10.1016/j.ejmech.2023.115490]
Al-Shawi A.A.A.; El-Arabey A.A.; Mutlaq D.Z.; Eltayb W.A.; Iriti M.; Abdalla M.; Study on molecular anti-tumor mechanism of 2-Thiohydantoin derivative based on molecular docking and bioinformatic analyses. Curr Top Med Chem 2023,23(6),440-452
[DOI:
10.2174/1568026623666230106121527]
Blanc M.; Cussac M.; Boucherle A.; Leclerc G.; Synthesis and immunomodulating activity of 1-amino-2-thiohydantoin derivatives. Eur J Med Chem 1992,27(8),839-843
[DOI:
10.1016/0223-5234(92)90119-L]
El-Sharief A.M.S.; Al-Amri A.M.; Al-Raqa S.Y.; Halogenated, alkylated and new types of imidazolidine, pyrrolidine, imidazotriazine and thienoimidazole derivatives with biological and antitumor activities. J Sulfur Chem 2006,27(3),245-263
[DOI:
10.1080/17415990600631316]
Tran C.; Ouk S.; Clegg N.J.; Chen Y.; Watson P.A.; Arora V.; Wongvipat J.; Smith-Jones P.M.; Yoo D.; Kwon A.; Wasielewska T.; Welsbie D.; Chen C.D.; Higano C.S.; Beer T.M.; Hung D.T.; Scher H.I.; Jung M.E.; Sawyers C.L.; Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009,324(5928),787-790
[DOI:
10.1126/science.1168175]
Nagarajan S.; Skoufias D.A.; Kozielski F.; Pae A.N.; Receptor-ligand interaction-based virtual screening for novel Eg5/kinesin spindle protein inhibitors. J Med Chem 2012,55(6),2561-2573
[DOI:
10.1021/jm201290v]
Majumdar P.; Bathula C.; Basu S.M.; Das S.K.; Agarwal R.; Hati S.; Singh A.; Sen S.; Das B.B.; Design, synthesis and evaluation of thiohydantoin derivatives as potent topoisomerase I (Top1) inhibitors with anticancer activity. Eur J Med Chem 2015,102,540-551
[DOI:
10.1016/j.ejmech.2015.08.032]
Wu F.; Jiang H.; Zheng B.; Kogiso M.; Yao Y.; Zhou C.; Li X.N.; Song Y.; Inhibition of cancer-associated mutant isocitrate dehydrogenases by 2-thiohydantoin compounds. J Med Chem 2015,58(17),6899-6908
[DOI:
10.1021/acs.jmedchem.5b00684]
Mariano M.; Hartmann R.W.; Engel M.; Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2. Eur J Med Chem 2016,112,209-216
[DOI:
10.1016/j.ejmech.2016.02.017]
Elhady H.A.; El-Sayed R.; Al-nathali H.S.; Design, synthesis and evaluation of anticancer activity of novel 2-thioxoimidazolidin-4-one derivatives bearing pyrazole, triazole and benzoxazole moieties. Chem Cent J 2018,12(1),51
[DOI:
10.1186/s13065-018-0418-1]
Arif I.A.; Ahamed A.; Kumar R.S.; Idhayadhulla A.; Manilal A.; Cytotoxic, larvicidal, nematicidal, and antifeedant activities of piperidin-connected 2-thioxoimidazolidin-4-one derivatives. Saudi J Biol Sci 2019,26(4),673-680
[DOI:
10.1016/j.sjbs.2017.12.007]
Elbadawi M.M.; Khodair A.I.; Awad M.K.; Kassab S.E.; Elsaady M.T.; Abdellatif K.R.A.; Design, synthesis and biological evaluation of novel thiohydantoin derivatives as antiproliferative agents: A combined experimental and theoretical assessments. J Mol Struct 2022,1249,131574
[DOI:
10.1016/j.molstruc.2021.131574]
Barrett R.R.G.; Nash C.; Diennet M.; Cotnoir-White D.; Doyle C.; Mader S.; Thomson A.A.; Gleason J.L.; Dual-function antiandrogen/HDACi hybrids based on enzalutamide and entinostat. Bioorg Med Chem Lett 2022,55,128441
[DOI:
10.1016/j.bmcl.2021.128441]
Nicolescu R.C.B.; Maylin Z.R.; Pérez-Areales F.J.; Iegre J.; Pandha H.S.; Asim M.; Spring D.R.; Hybrid androgen receptor inhibitors Outperform Enzalutamide and EPI‐001 in in vitro models of prostate cancer drug resistance. ChemMedChem 2023,18(2),e202200548
[DOI:
10.1002/cmdc.202200548]
Kim H.R.; Lee H.J.; Choi Y.J.; Park Y.J.; Woo Y.; Kim S.J.; Park M.H.; Lee H.W.; Chun P.; Chung H.Y.; Moon H.R.; Benzylidene-linked thiohydantoin derivatives as inhibitors of tyrosinase and melanogenesis: Importance of the β-phenyl-α,β-unsaturated carbonyl functionality. Med Chem Commun 2014,5(9),1410-1417
[DOI:
10.1039/C4MD00171K]
Evdokimov N.M.; Magedov I.V.; McBrayer D.; Kornienko A.; Isatin derivatives with activity against apoptosis-resistant cancer cells. Bioorg Med Chem Lett 2016,26(6),1558-1560
[DOI:
10.1016/j.bmcl.2016.02.015]
Xu X.; Ge R.; Li L.; Wang J.; Lu X.; Xue S.; Chen X.; Li Z.; Bian J.; Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents. Eur J Med Chem 2018,143,1325-1344
[DOI:
10.1016/j.ejmech.2017.10.031]
Channar P.A.; Bano S.; Hassan S.; Perveen F.; Saeed A.; Mahesar P.A.; Khan I.A.; Iqbal J.; Appraisal of novel azomethine–thioxoimidazolidinone conjugates as ecto-5′-nucleotidase inhibitors: Synthesis and molecular docking studies. RSC Adv 2022,12(27),17596-17606
[DOI:
10.1039/D2RA02675A]
Álvarez-Pérez M.; Ali W.; Marć M.; Handzlik J.; Domínguez-Álvarez E.; Selenides and Diselenides: A review of their anticancer and chemopreventive activity. Molecules 2018,23(3),628
[DOI:
10.3390/molecules23030628]
Radomska D.; Czarnomysy R.; Radomski D.; Bielawski K.; Selenium compounds as novel potential anticancer agents. Int J Mol Sci 2021,22(3),1009
[DOI:
10.3390/ijms22031009]
Koketsu M.; Takahashi A.; Ishihara H.; A facile preparation of selenohydantoins using isoselenocyanate. J Heterocycl Chem 2007,44(1),79-81
[DOI:
10.1002/jhet.5570440113]
Chennakrishnareddy G.; Nagendra G.; Hemantha H.P.; Das U.; Guru Row T.N.; Sureshbabu V.V.; Isoselenocyanates derived from Boc/Z-amino acids: Synthesis, isolation, characterization, and application to the efficient synthesis of unsymmetrical selenoureas and selenoureidopeptidomimetics. Tetrahedron 2010,66(34),6718-6724
[DOI:
10.1016/j.tet.2010.06.082]
Hemantha H.P.; Sureshbabu V.V.; Isoselenocyanates derived from amino acid esters: An expedient synthesis and application to the assembly of selenoureidopeptidomimetics, unsymmetrical Selenoureas and selenohydantoins. J Pept Sci 2010,16(11),644-651
[DOI:
10.1002/psc.1276]
Garud D.R.; Koketsu M.; Ishihara H.; Isoselenocyanates: A powerful tool for the synthesis of selenium-containing heterocycles. Molecules 2007,12(3),504-535
[DOI:
10.3390/12030504]
Ivanenkov Y.A.; Veselov M.S.; Rezekin I.G.; Skvortsov D.A.; Sandulenko Y.B.; Polyakova M.V.; Bezrukov D.S.; Vasilevsky S.V.; Kukushkin M.E.; Moiseeva A.A.; Finko A.V.; Koteliansky V.E.; Klyachko N.L.; Filatova L.A.; Beloglazkina E.K.; Zyk N.V.; Majouga A.G.; Synthesis, isomerization and biological activity of novel 2-selenohydantoin derivatives. Bioorg Med Chem 2016,24(4),802-811
[DOI:
10.1016/j.bmc.2015.12.050]
Żesławska E.; Kincses A.; Unger V.; Tóth V.; Spengler G.; Nitek W.; Tejchman W.; Exocyclic Sulfur and Selenoorganic compounds towards their anticancer effects: Crystallographic and biological studies. Anticancer Res 2018,38(8),4577-4584
[DOI:
10.21873/anticanres.12762]
Vyhivskyi O.; Dlin E.A.; Finko A.V.; Stepanova S.P.; Ivanenkov Y.A.; Skvortsov D.A.; Mironov A.V.; Zyk N.V.; Majouga A.G.; Beloglazkina E.K.; Copper-promoted C–Se cross-coupling of 2-Selenohydantoins with Arylboronic acids in an open flask. ACS Comb Sci 2019,21(6),456-464
[DOI:
10.1021/acscombsci.9b00021]
Vyhivskyi O.; Laikov D.N.; Finko A.V.; Skvortsov D.A.; Zhirkina I.V.; Tafeenko V.A.; Zyk N.V.; Majouga A.G.; Beloglazkina E.K.; Ullmann-type C–Se cross-coupling in the hydantoin family: Synthesis, mechanistic studies, and tests of biological activity. J Org Chem 2020,85(5),3160-3173
[DOI:
10.1021/acs.joc.9b03045]
Kukushkin M.; Novotortsev V.; Filatov V.; Ivanenkov Y.; Skvortsov D.; Veselov M.; Shafikov R.; Moiseeva A.; Zyk N.; Majouga A.; Beloglazkina E.; Synthesis and biological evaluation of S-, O- and Se-containing dispirooxindoles. Molecules 2021,26(24),7645
[DOI:
10.3390/molecules26247645]
Novotortsev V.K.; Kukushkin M.E.; Tafeenko V.A.; Skvortsov D.A.; Kalinina M.A.; Timoshenko R.V.; Chmelyuk N.S.; Vasilyeva L.A.; Tarasevich B.N.; Gorelkin P.V.; Erofeev A.S.; Majouga A.G.; Zyk N.V.; Beloglazkina E.K.; Dispirooxindoles based on 2-Selenoxo-Imidazolidin-4-Ones: Synthesis, cytotoxicity and ROS generation ability. Int J Mol Sci 2021,22(5),2613
[DOI:
10.3390/ijms22052613]
Finko A.V.; Sokolov A.I.; Guk D.A.; Tafeenko V.A.; Moiseeva A.A.; Skvortsov D.A.; Stomakhin A.A.; Beloglazkin A.A.; Borisov R.S.; Pergushov V.I.; Melnikov M.Y.; Zyk N.V.; Majouga A.G.; Beloglazkina E.K.; Copper coordination compounds with (5 Z, 5 Z ′)-2,2′-(alkane-α,ω-diyldiselenyl)-bis-5-(2-pyridylmethylene)-3,5-dihydro-4-H-imidazol-4-ones. Comparison with sulfur analogue. RSC Adv 2022,12(12),7133-7148
[DOI:
10.1039/D1RA08995A]
